4 completed, 2 recruiting, 2 withdrawn, 1 terminated. 9 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Completed 4, Recruiting 2, Withdrawn 2, Terminated 1 |
Follow Subcutaneous Emphysema: new trials by email Literature Review of Subcutaneous Emphysema trials Research Report on Subcutaneous Emphysema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD) CE1226 - Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency | Phase 4 | Recruiting | CSL Behring | 270 | 2026-09-29 | 2026-10-16 |
| Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency 20-valent pneumococcal conjugate vaccine - Alpha 1-Antitrypsin, COPD | Phase 4 | Recruiting | University of Alabama at Birmingham | 30 | 2025-09-03 | 2026-10-27 |
| A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema RYMPHYSIA, Another Available A1PI - Chronic Obstructive Pulmonary Disease (COPD), Alpha1-Antitrypsin Deficiency | Phase 4 | Withdrawn | Takeda | 2024-01-01 | 2023-05-06 | |
| ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study ARALAST NP - Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency | Phase 4 | Withdrawn | Shire | 2021-03-08 | 2020-09-14 | |
| GLASSIA Infusion Rate Study Alpha1-proteinase inhibitor, Placebo: Human albumin 2.5% - Alpha1-antitrypsin Deficiency, Healthy Volunteers | Phase 4 | Completed | Baxalta now part of Shire | 30 | 2012-07-31 | 2021-05-25 |
| Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency. Alpha1- proteinase inhibitor [human] - Emphysema, Alpha 1-proteinase Inhibitor Deficiency | Phase 4 | Completed | CSL Behring | 140 | 2008-04-01 | 2016-08-15 |
| Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor) Alpha1-Proteinase Inhibitor - Alpha 1-Antitrypsin Deficiency | Phase 4 | Completed | Baxalta now part of Shire | 21 | 2006-10-27 | 2021-05-13 |
| Aralast alpha1-proteinase Inhibitor Surveillance Study ARALAST Alpha1-Proteinase Inhibitor - Alpha1-antitrypsin Deficiency | Phase 4 | Terminated | Baxalta now part of Shire | 127 | 2006-06-09 | 2021-05-26 |
| Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency Alpha1-proteinase inhibitor, Placebo - Alpha1-proteinase Inhibitor Deficiency, Emphysema | Phase 4 | Completed | CSL Behring | 180 | 2006-03-01 | 2015-01-19 |
alpha 1-Antitrypsin Deficiency (9) · Emphysema (3) · Pulmonary Disease, Chronic Obstructive (3) · Disease (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Digestive System Diseases (9) · Genetic Diseases, Inborn (9) · Liver Diseases (9) · Lung Diseases (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Respiratory Tract Diseases (9) · Emphysema (6) · Chronic Disease (3) · Disease Attributes (3) · Lung Diseases, Obstructive (3)
alpha 1-Antitrypsin (7) · Respreeza (2)
Baxalta now part of Shire (3) · CSL Behring (3) · Shire (1) · Takeda (1) · University of Alabama at Birmingham (1)
United States (4) · Australia (3) · Denmark (3) · Canada (2) · Czechia (2) · Estonia (2) · Finland (2) · Germany (2) · Ireland (2) · Poland (2) · Romania (2) · Sweden (2) · New Zealand (1) · Russia (1)
PMID 26026936, PMID 30237305, PMID 27916480, PMID 36001294
2005 (1), 2025 (1)